Benjamin L. Palleiko

2019

In 2019, Benjamin L. Palleiko earned a total compensation of $2.1M as Chief Business Officer and Chief Financial Officer at Carbylan Therapeutics, a 155% increase compared to previous year.

Compensation breakdown

Bonus$192,150
Option Awards$994,555
Salary$366,000
Stock Awards$527,794
Other$11,000
Total$2,091,499

Palleiko received $994.6K in option awards, accounting for 48% of the total pay in 2019.

Palleiko also received $192.2K in bonus, $366K in salary, $527.8K in stock awards and $11K in other compensation.

Rankings

In 2019, Benjamin L. Palleiko's compensation ranked 5,698th out of 13,971 executives tracked by ExecPay. In other words, Palleiko earned more than 59.2% of executives.

ClassificationRankingPercentile
All
5,698
out of 13,971
59th
Division
Manufacturing
2,132
out of 5,701
63rd
Major group
Chemicals And Allied Products
766
out of 2,200
65th
Industry group
Drugs
643
out of 1,886
66th
Industry
Pharmaceutical Preparations
470
out of 1,398
66th
Source: SEC filing on August 23, 2019.

Palleiko's colleagues

We found three more compensation records of executives who worked with Benjamin L. Palleiko at Carbylan Therapeutics in 2019.

2019

T Crockett

Carbylan Therapeutics

Chief Executive Officer

2019

Edward Feener

Carbylan Therapeutics

Chief Scientific Officer

2019

Christopher Yea

Carbylan Therapeutics

Chief Development Officer

News

You may also like